Navigation Links
Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Date:9/4/2007

CORONA, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has received its first U.S. Food and Drug Administration (FDA) product approval at its Goa, India facility. During the next several months the company plans to seek FDA approval to manufacture additional solid dosage products at the facility. By early 2008, the Goa facility is expected to be producing over 1 billion tablets and capsules annually for the U.S. market.

"This approval represents a key milestone for Watson, demonstrating our rapid progress toward building an offshore infrastructure," said Allen Chao, Ph.D., Watson's Executive Chairman. "In the coming months we anticipate making additional FDA submissions to transfer certain products to this facility to achieve efficiencies in scale and cost. This will enhance our ability to provide quality, low cost generic pharmaceutical products to the U.S. marketplace."

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, difficulties or delays in transferring product manufacturing to the Goa facility; difficulties or delays in obtaining U.S. Food and Drug Administration or other regulatory approvals to manufacture products at the Goa, India site for the U.S. market; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. FDA approves Watson Pharmaceuticals Oxytrol patch
2. Pravastatin Launched by Watson Pharmaceuticals
3. Watson Amazed by Radcliffes Steamy Shots
4. Infant receives first bloodless liver transplant
5. Fifth US Patient Receives Artificial Heart
6. Northfield Labs Receives FDA Comments
7. British MPs Say Prostate Cancer Receives Low Priority in the NHS
8. Abbott Receives CE Mark Certification
9. Zactima Receives Fast Track Designation By The FDA
10. East London Receives World Class New Private Hospital Facility
11. Brinda Karat Receives Legal Notice over Ramdev Issue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... 22, 2017 , ... ANGLESTRONG , the new recovery management app with ... App Store and Google Play . Florida-based Sober Network, Inc., the ... industry, partnered with Angle to build ANGLESTRONG. The new recovery management app is a ...
(Date:2/22/2017)... ... February 22, 2017 , ... A product of digesting a ... derive a heart-protective benefit from eating soy foods, while others do not, a University ... are able to produce equol—a substance made by some types of “good” gut bacteria ...
(Date:2/22/2017)... ... 2017 , ... Super-Sod will attend the Athens Home Show with a brand ... shift from Super-Sod’s simple Athens Home Show booth of 2016, this year’s exhibit space ... manager Chris Roquemore constructed furniture from recycled pallet wood at the Super-Sod farm in ...
(Date:2/22/2017)... ... February 22, 2017 , ... BrightStar Care Charleston , a home ... University of South Carolina (MUSC) Center on Aging’s Senior Expo on Thursday, March ... Aging is a tremendous resource in our community. We are thrilled to participate in ...
(Date:2/22/2017)... ... February 22, 2017 , ... Apptricity® Corporation, a leading global ... management, today announced that Keppel Corporation has selected Apptricity Travel and Expense Management ... “We are excited to announce the partnership between Keppel and Apptricity for our ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), ... fiscal year ended December 31, 2016. ... This news release should ... and management discussion and analysis for the years ended December ... and are available at www.sedar.com and on the ...
(Date:2/22/2017)... Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) ... 2016 investor conference call and webcast at 8:30 a.m., Eastern ... will cover an update on Merrimack,s recent progress as well ... financial results. A press release detailing the information to be ... Wednesday, March 1. Investors and the general public are invited ...
(Date:2/22/2017)... 2017 Summary Provides understanding and ... and agreements entered into by the worlds leading healthcare ... Description The Global Non-Small Cell Lung Cancer Partnering ... access to partnering deals and agreements entered into by ... in partnering deals - Top deals by value ...
Breaking Medicine Technology: